OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROXIMUS
- 31 Aug 2018 Biomarkers information updated
- 17 Apr 2018 Status changed from recruiting to completed.
- 09 Jan 2017 Planned number of patients changed from 60 to 30.